Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul-Sep;46(3):e20230146.
doi: 10.1590/2175-8239-JBN-2023-0146en.

Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?

[Article in English, Portuguese]
Mauricio de Carvalho  1   2 , Ita Pfeferman Heilberg  3
Affiliations
Review

Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?

[Article in English, Portuguese]
Mauricio de Carvalho et al. J Bras Nefrol. 2024 Jul-Sep.

Abstract
in English, Portuguese

The prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?

RESUMO: A prevalência da nefrolitíase está aumentando em todo o mundo. Apesar dos avanços na compreensão da patogênese da doença litiásica, poucos estudos demonstraram que intervenções clínicas específicas diminuem a recorrência da nefrolitíase. O objetivo desta revisão é analisar os dados atuais e efeitos potenciais dos iSGLT2 na doença litiásica e tentar responder à pergunta: devemos também “gliflozinar” os litiásicos?

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare that there is no conflict of interest related to the article.

Figures

Figure 1
Figure 1. SGLT2 is located at the beginning (S1) of the proximal tubule, and it is responsible for 80–90% of the filtered glucose reabsorption. SGLT1 is on the most distal portion of the proximal tubule (S2/S3) and it is responsible for reabsorbing the 10–20% remaining of the filtered glucose.
Figura 1
Figura 1. O SGLT2 está localizado no início (S1) do túbulo proximal e é responsável pela reabsorção de 80–90% da glicose filtrada. O SGLT1 está localizado na parte mais distal do túbulo proximal (S2/S3) e é responsável pela reabsorção dos restantes 10–20% da glicose filtrada.
See this image and copyright information in PMC

References

    1. Shepard BD, Pluznick JL. Saving the sweetness: renal glucose handling in health and disease. Am J Physiol Renal Physiol. 2017;313(1):F55–61. doi: 10.1152/ajprenal.00046.2017. - DOI - PMC - PubMed
    1. Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24(10):8732. doi: 10.3390/ijms24108732. - DOI - PMC - PubMed
    1. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–41. doi: 10.2215/CJN.04010609. - DOI - PubMed
    1. Tsujihara K, Hongu M, Saito K, Inamasu M, Arakawa K, Oku A, et al. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo). 1996;44(6):1174–80. doi: 10.1248/cpb.44.1174. - DOI - PubMed
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71. doi: 10.1056/NEJMoa072761. - DOI - PubMed

MeSH terms

Substances